Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(892)
•••
Comment by westcoast1000on Apr 16, 2023 2:09pm
255 Views
Post# 35397446

RE:RE:RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

RE:RE:RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.KTDfyi,

I like your optimism.

If we get news in June that was as good as the news in December, and then we somehow announce plausible plans for Ph 3s, we can expect the share price to finally go up.

Once it starts going up, it should overcome the huge ONCY skepticism that exists out there. Then we could get to the average share price of a small bio with two ph 3s. 

What that is worth I do not know, but I would expect it to be over $ 1 billion US. At that level the share price would be roughly $15 US. 

So more good news and ph 3s  will lead to greater confidence, higher prices, institutional interest and some relief for long suffering ONCY holders. When to sell will become a decision with postive choices instead of negative ones. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities